A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation

NCT04201418 · clinicaltrials.gov ↗

COMPLETED

Status

67

Enrollment

INDUSTRY

Sponsor class

Conditions

Hereditary Transthyretin-mediated (ATTRv) Amyloidosis
Polyneuropathy

Interventions

DRUG: Patisiran

Sponsor

Alnylam Pharmaceuticals